Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Jade Biosciences (JBIO)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Jade Biosciences, with a price target of $42.00. The company’s shares closed last Friday at $16.94.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 26.8% and a 49.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Amylyx Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jade Biosciences with a $49.00 average price target, a 179.7% upside from current levels. In a report issued on June 1, William Blair also maintained a Buy rating on the stock.
